Know Cancer

or
forgot password

A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms


Phase 1
1 Year
21 Years
Open (Enrolling)
Both
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific

Thank you

Trial Information

A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms


OBJECTIVES:

Primary

- To estimate the maximum-tolerated dose and/or recommended phase II dose of oral JAK
inhibitor INCB18424 administered continuously, twice daily to pediatric patients with
relapsed or refractory solid tumors.

- To define and describe the toxicities of this treatment administered on this schedule
in pediatric patients with relapsed or refractory solid tumors, leukemias, or
myeloproliferative neoplasms (MPNs).

- To characterize the pharmacokinetics of this treatment in pediatric patients with
relapsed or refractory solid tumors, leukemias, or MPNs.

Secondary

- To preliminarily define the antitumor activity of this treatment within the confines of
a phase I study.

- To assess the biologic activity of oral JAK inhibitor INCB18424 upon JAK-STAT signaling
in pediatric patients with relapsed or refractory solid tumors, leukemias, or MPNs.

- To assess the cytotoxicity and biologic activity of oral JAK inhibitor INCB18424 upon
phosphosignaling and mutation burden in pediatric patients whose leukemias or MPNs have
known CRLF2 and/or JAK mutations.

OUTLINE: This is a multicenter, dose-escalation study.

Patients receive oral JAK inhibitor INCB18424 twice daily on days 1-28. Courses repeat every
28 days in the absence of disease progression or unacceptable toxicity.

Patients with relapsed or refractory leukemia may receive intrathecal chemotherapy in course
2 and subsequent courses at the discretion of the treating physician.

Plasma, bone marrow, and blood samples may be collected at baseline, during course 1, and
before subsequent courses for pharmacokinetic analysis and correlative biology studies.

After completion of study treatment, patients are followed up for 30 days.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed diagnosis of one of the following:

- Relapsed or refractory extracranial solid tumor

- Relapsed or refractory leukemia

- At least 25% blasts in the bone marrow (M3) with the exception of patients
with acute myeloid leukemia (AML), who must have > 20% blasts in the bone
marrow

- Relapsed or refractory myeloproliferative neoplasm (MPN)

- At original diagnosis or relapse

- Current diagnostic criteria for MPNs include polycythemia vera, essential
thrombocythemia, juvenile myelomonocytic leukemia, myelofibrosis, and
atypical chronic myeloid leukemia

- Relapsed or refractory leukemia or MPN that have confirmed JAK mutations and/or
positive TSLPR surface staining

- Testing for JAK mutations and/or confirmed positive flow cytometry surface
staining for the thymic stromal lymphopoietin receptor (TSLPR; encoded by
CRLF2) must be performed by a CLIA-approved laboratory

- Measurable or evaluable disease (for patients with solid tumors)

- Current disease state is one for which there is no known curative therapy or therapy
proven to prolong survival with an acceptable quality of life

- No known active CNS involvement (radiographic or cytologic)

PATIENT CHARACTERISTICS:

- Karnofsky performance status (PS) 50-100% (for patients > 16 years old) or Lansky PS
50-100% (for patients ≤ 16 years old)

- Patients who are unable to walk because of paralysis, but who can actively sit
up in a wheelchair, will be considered ambulatory for the purpose of assessing
the performance status

- Patients with solid tumors* must meet the following criteria:

- Peripheral ANC ≥ 1,000/mm^3

- Platelet count ≥ 100,000/mm^3 (transfusion-independent, defined as > 7 days
since prior platelet transfusions)

- Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)

- Not refractory to to red cell or platelet transfusion

- ALT ≤ 110 U/L NOTE: *Patients with solid tumors and known bone marrow metastatic
disease are eligible for study, but not evaluable for hematologic toxicity.
These patients must not be known to be refractory to RBC or platelet
transfusions.

- Patients with leukemia or MPNs must meet the following criteria:

- Platelet count ≥ 20,000/mm^3 (may receive platelet infusions)

- Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)

- ALT ≤ 225 U/L

- Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on
age/gender as follows:

- ≤ 0.6 mg/dL (for patients 1 to < 2 years old)

- ≤ 0.8 mg/dL (for patients 2 to < 6 years old)

- ≤ 1 mg/dL (for patients 6 to < 10 years old)

- ≤ 1.2 mg/dL (for patients 10 to < 13 years old)

- ≤ 1.4 mg/dL (for female patients ≥ 13 years old)

- ≤ 1.5 mg/dL (for male patients 13 to < 16 years old)

- ≤ 1.7 mg/dL (for male patients ≥ 16 years old)

- Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 times upper limit of normal for
age

- Serum albumin ≥ 2 g/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able to swallow crushed or whole tablets

- Nasogastric or G tube administration is not allowed

- Body surface area ≥ 0.65 m^2 (for patients at dose level -1, 1, and 2)

- No uncontrolled infection, including patients with known active HIV or chronic
hepatitis

- No patients who, in the opinion of the investigator, may not be able to comply with
the safety monitoring requirements of the study

PRIOR CONCURRENT THERAPY:

- Fully recovered from the acute toxic effects of all prior anticancer therapy

- At least 2 weeks since prior local palliative radiotherapy (small port)

- At least 6 months since prior total-body irradiation (TBI), craniospinal
radiotherapy, or radiotherapy to ≥ 50% of the pelvis (for patients with solid tumors)

- At least 3 months since prior TBI, craniospinal radiotherapy, or radiotherapy to ≥
50% of the pelvis (for patients with leukemia)

- At least 3 months since prior stem cell transplantation or rescue without TBI and no
evidence of active graft-vs-host disease

- At least 6 weeks since other substantial bone marrow radiation

- At least 3 weeks since prior myelosuppressive therapy (6 weeks for nitrosourea) (for
patients with solid tumors)

- At least 2 weeks since prior cytoxic chemotherapy (for patients with leukemia or
MPNs)

- Hydroxyurea may be initiated and continued for up to 24 hours before the start
of study treatment

- Intrathecal cytarabine (Ara-C) is not myelosuppressive chemotherapy

- Patients with leukemia are permitted to receive intrathecal chemotherapy,
including methotrexate or cytarabine, only if this is given at the time of
diagnostic lumbar puncture at least 24 hours prior to the start of INCB018424

- At least 2 weeks since prior long-acting hematopoietic growth factor (e.g., Neulasta)
or 1 week for a short-acting growth factor

- For agents that have known adverse events occurring beyond 1 week, this period
must be extended beyond the time during which adverse events are known to occur
(as discussed with the study chair)

- At least 1 week since prior therapy with a biologic (antineoplastic) agent

- For agents that have known adverse events occurring beyond 1 week, this period
must be extended beyond the time during which adverse events are known to occur
(as discussed with the study chair)

- At least 3 half-lives of antibody since prior monoclonal antibody

- No other concurrent investigational drugs

- No other concurrent anticancer agents, including chemotherapy, radiotherapy,
immunotherapy, or biologic therapy

- No concurrent systemic steroids (i.e., prednisone > 10 mg)

- No concurrent aspirin > 150 mg/day

- No concurrent medications for myelofibrosis (e.g., hydroxyurea, interferon,
thalidomide, busulfan, lenalidomide, or anagrelide)

- No concurrent cyclosporine, tacrolimus, or other agents to prevent graft-vs-host
disease after bone marrow transplant or organ rejection after transplant

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Outcome Measure:

Maximum-tolerated dose and/or recommended phase II dose

Safety Issue:

Yes

Principal Investigator

Mignon Loh, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of California, San Francisco

Authority:

Unspecified

Study ID:

CDR0000680970

NCT ID:

NCT01164163

Start Date:

September 2010

Completion Date:

Related Keywords:

  • Chronic Myeloproliferative Disorders
  • Leukemia
  • Myelodysplastic Syndromes
  • Myelodysplastic/Myeloproliferative Neoplasms
  • Unspecified Childhood Solid Tumor, Protocol Specific
  • unspecified childhood solid tumor, protocol specific
  • recurrent childhood acute lymphoblastic leukemia
  • recurrent childhood acute myeloid leukemia
  • refractory chronic lymphocytic leukemia
  • relapsing chronic myelogenous leukemia
  • childhood myelodysplastic syndromes
  • previously treated myelodysplastic syndromes
  • atypical chronic myeloid leukemia, BCR-ABL1 negative
  • chronic myelomonocytic leukemia
  • juvenile myelomonocytic leukemia
  • myelodysplastic/myeloproliferative neoplasm, unclassifiable
  • polycythemia vera
  • essential thrombocythemia
  • childhood acute promyelocytic leukemia (M3)
  • acute myeloid leukemia/transient myeloproliferative disorder
  • primary myelofibrosis
  • Neoplasms
  • Leukemia
  • Myelodysplastic Syndromes
  • Preleukemia
  • Myeloproliferative Disorders
  • Myelodysplastic-Myeloproliferative Diseases

Name

Location

Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania  19104
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland  21231-2410
Children's Hospital of Orange CountyOrange, California  92668
Children's National Medical CenterWashington, District of Columbia  20010-2970
Children's Hospital and Regional Medical Center - SeattleSeattle, Washington  98105
Children's Memorial Hospital - ChicagoChicago, Illinois  60614
St. Jude Children's Research HospitalMemphis, Tennessee  38105-2794
Midwest Children's Cancer Center at Children's Hospital of WisconsinMilwaukee, Wisconsin  53226
Cincinnati Children's Hospital Medical CenterCincinnati, Ohio  45229-3039
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - DallasDallas, Texas  75390
Baylor University Medical Center - HoustonHouston, Texas  77030-2399
UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, California  94115
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston CampusAtlanta, Georgia  30322
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer InstituteBoston, Massachusetts  02115
C.S. Mott Children's Hospital at University of Michigan Medical CenterAnn Arbor, Michigan  48109-0286
Masonic Cancer Center at University of MinnesotaMinneapolis, Minnesota  55455
Siteman Cancer Center at Barnes-Jewish Hospital - Saint LouisSt. Louis, Missouri  63110
Herbert Irving Comprehensive Cancer Center at Columbia University Medical CenterNew York, New York  10032
Knight Cancer Institute at Oregon Health and Science UniversityPortland, Oregon  97239-3098
Children's Hospital of Pittsburgh of UPMCPittsburgh, Pennsylvania  15213
Riley's Children Cancer Center at Riley Hospital for ChildrenIndianapolis, Indiana  46202-5225
UAB Comprehensive Cancer CenterBirmingham, Alabama  35294
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral OfficeBethesda, Maryland  20892-1182
Children's Hospital Colorado Center for Cancer and Blood DisordersAurora, Colorado  80045